the aid library

LIST OPTIONS

Filter

2880

Interim Guidance on the Use of Rapid Antibody Tests for COVID-19 Response
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2020) CC

The speed of developing diagnostics for SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), has been quite remarkable. Diagnostics have focused on nucleic acid amplification testing (NAAT) to identify infected individuals in acute-phase disease for timely implementation of mitiga... more

External Link

Preparedness and Response for Chikungunya Virus Introduction in the Americas
recommended

Pan American Health Organization; Centers for Disease Control and Prevention CDC (2011) C_WHO

Download (181)

View PDF (328)

Research Methods for Promotion of Lung Health

D. A. Enarson, S. M. Kennedy, D. L. Miller, et al. International Union Against Tuberculosis and Lung Disease (2001)

A guide to protocol development for low-income countries

Download (182)

View PDF (463)

Partnerships for African Vaccine Manufacturing (PAVM) Framework for Action

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

The African Centers for Disease Control and Prevention and the African Union together have called for a New Public Health Order which will safeguard the health and economic security of the continent as it strives to meet the aspirations of the Agenda 2063. A key pillar of this mandate seeks to expan... more

External Link

DNDi Strategic Plan 2021-2028 | DNDi - English version

DNDi - Drugs for neglected diseases initiative (2023) C2

Accessed on 04.04.2023 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients

External Link

Preparación y respuesta ante la eventual introducción del virus chikungunya en las Américas

Organización Panamericana de la Salud; Centers for Disease Control and Prevention (2011)

Download (118)

View PDF (157)

Africa CDC Event-based Surveillance Framework: interim version 2018

African Union; Africa CDC Centres for Disease Control and Prevention Africa CDC (2018) CC

Event-based surveillance (EBS) is defined as the organized collection, monitoring, assessment and interpretation of mainly unstructured ad hoc information regarding health events or risks, which may represent an acute risk to health. Both indicator-based and event-based surveillance components serve... more

Public Health Emergency Operations Center (PHEOC) Legal Framework Guide

African Union; Africa CDC Centres for Disease Control and Prevention (2021) CC

A public health emergency operation center (PHEOC) serves as a hub for better coordinating the preparation, response, and recovery for public health emergencies. A functional PHEOC is critical for the implementation of the International Health Regulations (IHR 2005). The Framework for a Public Healt... more

Download (451)

View PDF (768)

The looming co-epidemic of of TB-Diabetes

World Diabetes Foundation; International Union against Tuberculosis and Lung Disease (2017)

Accessed November 2017.

Download (347)

View PDF (1144)

Tuberculosis surveillance and monitoring in Europe 2020-2019 data

World Health Organization; European Centre for disease prevention and Control (2021) C_WHO

Surveillance Report

Download (304)

View PDF (723)

Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants

A. C. Hesseling, M. F. Cotton, C. F. von Reyn, et al. CG Working Group, Child Lung Health Section, International Union Against Tuberculosis and Lung Disease (2008)

Offical Statement INT J TUBERC LUNG DIS 12(12):1376–1379

Download (372)

View PDF (511)

The Men Are Away: Pregnancy Risk and Family Planning Needs among Women with a Migrant Husband in Barisal, Bangladesh

Khan, Rasheda, Kerry L. D. MacQuarrie, Quamrun Nahar, and Marzia Sultana National Institute of Population Research and Training (NIPORT), International Center for Diarrhoeal Disease Research, Bangladesh (icddr,b), and ICF International (2016) C1

DHS Further Analysis Reports No. 98

Download (108)

View PDF (163)

HIV/AIDS surveillance in Europe 2017

A. Pharris; A. Stengaard World Health Organization (Europe); European Centre for Disease Prevention and Control (2017) C_WHO

2016 data The report was coordinated by Anastasia Pharris and Annemarie Stengaard. Report review and production support were provided by Andrew J. Amato-Gauci, Mike Catchpole, Denis Coulombier, Masoud Dara, Nedret Emiroglu, Rachel Katterl, Shahin Khasiyev, Valentina Lazdina, Teymur Noori, Marc... more

Download (856)

View PDF (1183)

Zambia Demographic and Health Survey 2007

Central Statistical Office Lusaka; Ministry of Health Zambia; Tropical Diseases Research Centre, Zambia, DHS; et al. (2009) C1

External Link

The global burden of chromoblastomycosis

Santos, D.; Pedrozo e Silva de Azevedo, C.; Aparecida Vincent, V. et al. (2021) CC

Chromoblastomycosis (CBM), represents one of the primary implantation mycoses caused by melanized fungi widely found in nature. It is characterized as a Neglected Tropical Disease (NTD) and mainly affects populations living in poverty with significant morbidity, including stigma and discrimination.

COVID-19: Strategic preparedness and response plan for WHO African Region 1 February 2021-31 January 2022 (Update of 16 April 2021)

World Health Organization WHO, Regional Office of Africa; UNICEF (2021) C_WHO

The 2021 COVID-19 Strategic Preparedness and Response Plan (SPRP) for AFR serves as a regional guide for a holistic public health response to COVID‑19 at regional, national and sub-national levels. The 2021 SPRP: 1. Builds upon the lessons learnt from the implementation of the 2020 SPRP and outl... more

Strategic Framework for Enhancing Prevention and Control of mpox, 2024-2027

World Health Organization WHO (2024) C_WHO

Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani... more

External Link

COVID-19 in Malawi: lessons in pandemic preparedness from a tertiary children’s hospital

Chaziya J, Freyne B, Lissauer S et al. (2021) CC

Archives of Disease in Childhood 2021;106:238-240.

Download (342)

View PDF (565)

Weak surveillance and policy attention to cancer in global health: the example of Mozambique

Lorenzoni, C; Oliveras, Laura; Vilajeliu, A, et al. (2018) CC

Cancer is an emerging public health problem in sub-Saharan Africa due to population growth, ageing and westernisation of lifestyles. In this piece, we use data from Mozambique over a 50-year period to illustrate cancer epidemiological trends in low-income and middle-income countries to hypothesise ... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Interim Guidance on the Use of Rapid Antibody Tests for COVID-19 Response recommended

Preparedness and Response for Chikungunya Virus Introduction in the Americas recommended

Interim Guidance on the Use of Rapid Antibody Tests for COVID-19 Response
recommended

Preparedness and Response for Chikungunya Virus Introduction in the Americas
recommended